Acumen Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Acumen Pharmaceuticals, Inc.
Gene-editing focused start-ups Beam Therapeutics, Gracell, Snipr Biome and Precision Biosciences raised a total of $310m in financings in February and March. For other recent venture funding deals...
Neuroscience track at the Therapeutic Area Partnerships conferencewill feature novel candidates for Alzheimer’s, depression, traumatic brain injury, Fragile X syndrome and post-herpetic neuralgia.
Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Recent Financings Of Private Companies column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies in the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.
Merck & Co has terminated a 2003 agreement with Acumen Pharmaceuticals and returned rights to develop and commercialise its anti-amyloid-derived diffusible ligand (ADDL) antibody therapeutics and diagnostics for Alzheimer's disease.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Drug Discovery Tools